IN2014MN02644A - - Google Patents
Info
- Publication number
- IN2014MN02644A IN2014MN02644A IN2644MUN2014A IN2014MN02644A IN 2014MN02644 A IN2014MN02644 A IN 2014MN02644A IN 2644MUN2014 A IN2644MUN2014 A IN 2644MUN2014A IN 2014MN02644 A IN2014MN02644 A IN 2014MN02644A
- Authority
- IN
- India
- Prior art keywords
- compound
- amorphous
- crystalline
- aza
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Amorphous and crystalline solid forms of the anti HCV compound (1 {3 [6 (9 9 difluoro 7 {2 [5 (2 methoxycarbonylamino 3 methyl butyryl) 5 aza spiro[2.4]hept 6 yl] 3H imidazol 4 yl} 9H fluoren 2 yl) 1H benzoimidazol 2 yl] 2 aza bicyclo[2.2.1]heptane 2 carbonyl} 2 methyl propyl) carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: (Compound (I)). Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261655934P | 2012-06-05 | 2012-06-05 | |
US201361759295P | 2013-01-31 | 2013-01-31 | |
US13/800,374 US8969588B2 (en) | 2012-06-05 | 2013-03-13 | Solid forms of an antiviral compound |
PCT/US2013/044138 WO2013184698A1 (en) | 2012-06-05 | 2013-06-04 | Solid forms of an antiviral compound |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN02644A true IN2014MN02644A (en) | 2015-10-16 |
Family
ID=49670993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2644MUN2014 IN2014MN02644A (en) | 2012-06-05 | 2013-06-04 |
Country Status (20)
Country | Link |
---|---|
US (4) | US8969588B2 (en) |
EP (1) | EP2855478B1 (en) |
JP (2) | JP2015518891A (en) |
KR (1) | KR20150028971A (en) |
CN (2) | CN104379584A (en) |
AR (1) | AR091259A1 (en) |
AU (1) | AU2013271768B2 (en) |
BR (1) | BR112014030400A2 (en) |
CA (1) | CA2875507A1 (en) |
ES (1) | ES2694759T3 (en) |
HK (1) | HK1205127A1 (en) |
IL (1) | IL236004A0 (en) |
IN (1) | IN2014MN02644A (en) |
MX (1) | MX2014014563A (en) |
PT (1) | PT2855478T (en) |
RU (1) | RU2014150437A (en) |
SG (1) | SG11201408013WA (en) |
TW (1) | TW201408661A (en) |
UY (1) | UY34844A (en) |
WO (1) | WO2013184698A1 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005003147A2 (en) | 2003-05-30 | 2005-01-13 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
NZ706236A (en) | 2009-05-13 | 2016-07-29 | Gilead Pharmasset Llc | Antiviral compounds |
BR112013028886A2 (en) | 2011-05-10 | 2016-08-09 | Gilead Sciences Inc | fused heterocyclic compounds as sodium channel modulators |
UA116087C2 (en) | 2011-09-16 | 2018-02-12 | Гіліад Фармассет Елелсі | Methods for treating hcv |
US9056860B2 (en) | 2012-06-05 | 2015-06-16 | Gilead Pharmasset Llc | Synthesis of antiviral compound |
TW201446286A (en) * | 2013-01-31 | 2014-12-16 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
KR20140119012A (en) | 2013-01-31 | 2014-10-08 | 길리어드 파마셋 엘엘씨 | Combination formulation of two antiviral compounds |
CN104211565A (en) * | 2013-05-31 | 2014-12-17 | 浙江九洲药业股份有限公司 | Preparation method of anti-hepatitis c medicine intermediate |
ES2900570T3 (en) | 2013-08-27 | 2022-03-17 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
CN104513223B (en) * | 2014-11-20 | 2017-07-14 | 上海众强药业有限公司 | The preparation method of fluorenes ethanone derivatives |
US20180008624A1 (en) | 2015-02-13 | 2018-01-11 | Sandoz Ag | Pharmaceutical Compositions Comprising Ledipasvir And Sofosbuvir |
WO2016145269A1 (en) | 2015-03-12 | 2016-09-15 | Teva Pharmaceuticals International Gmbh | Solid state forms ledipasvir and processes for preparation of ledipasvir |
CN104788361B (en) * | 2015-04-21 | 2017-06-30 | 杭州科巢生物科技有限公司 | The synthetic method of the formic acid derivates of 5 azaspiros [2.4] heptane 6 |
WO2016193919A1 (en) | 2015-06-05 | 2016-12-08 | Mylan Laboratories Limited | Polymorphic form of ledipasvir |
CN104961733B (en) * | 2015-07-06 | 2019-04-09 | 上海众强药业有限公司 | Lei Dipawei crystal form and preparation method thereof |
WO2017072596A1 (en) | 2015-10-26 | 2017-05-04 | Optimus Drugs (P) Ltd | An improved process for the preparation of ledipasvir |
CN106608870A (en) * | 2015-10-26 | 2017-05-03 | 广东东阳光药业有限公司 | Preparation method for ledipasvir impurities |
CN105237517B (en) * | 2015-10-30 | 2017-10-27 | 南京正大天晴制药有限公司 | Lei Dipawei compounds of crystallization and preparation method thereof |
WO2017072714A1 (en) | 2015-10-30 | 2017-05-04 | Lupin Limited | Stable ledipasvir premix and process of preparation thereof |
CN105237384B (en) * | 2015-11-06 | 2017-06-30 | 上海万溯化学有限公司 | A kind of preparation method of polysubstituted fluorene derivative |
EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
CN106008316B (en) * | 2016-06-17 | 2018-04-27 | 成都百事兴科技实业有限公司 | A kind of method of synthesis Lei Dipawei chiral intermediates |
CN106699740A (en) * | 2016-12-26 | 2017-05-24 | 上海博志研新药物技术有限公司 | Ledipasvir and sofosbuvir compound tablet and preparation method and applications thereof |
US10392370B2 (en) | 2017-03-13 | 2019-08-27 | Optimus Drugs Pvt Ltd | Process for the preparation of Daclatasvir dihydrochloride and its intermediates |
CN109053400A (en) * | 2018-08-24 | 2018-12-21 | 江苏工程职业技术学院 | A kind of preparation method of Lei Dipawei key intermediate |
US11378965B2 (en) | 2018-11-15 | 2022-07-05 | Toyota Research Institute, Inc. | Systems and methods for controlling a vehicle based on determined complexity of contextual environment |
CN109678686A (en) * | 2018-12-19 | 2019-04-26 | 江苏工程职业技术学院 | A kind of preparation method of anti-hepatitis drug Lei Dipawei key intermediate |
JP2024519910A (en) | 2021-05-21 | 2024-05-21 | ギリアード サイエンシーズ, インコーポレイテッド | Pentacyclic derivatives as Zika virus inhibitors |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US6482847B2 (en) * | 2000-10-03 | 2002-11-19 | Hoffmann-La Roche Inc. | Amorphous form of cell cycle inhibitor having improved solubility and bioavailability |
US20070129385A1 (en) * | 2003-08-28 | 2007-06-07 | Sharma Mukesh K | Amorphous valganciclovir hydrochloride |
CN100448879C (en) * | 2004-07-22 | 2009-01-07 | 北京化工大学 | Method for preparing unformed cefuroxime axetil |
US20100076047A1 (en) * | 2007-08-20 | 2010-03-25 | Sankar Reddy Budidet | Amorphous 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol phosphate salt |
KR20100031045A (en) * | 2008-09-11 | 2010-03-19 | 씨제이제일제당 (주) | Method for purification of adefovir dipivoxil |
NZ706236A (en) | 2009-05-13 | 2016-07-29 | Gilead Pharmasset Llc | Antiviral compounds |
WO2010134045A1 (en) * | 2009-05-20 | 2010-11-25 | Ranbaxy Laboratories Limited | Amorphous fosamprenavir calcium |
CN102471320A (en) * | 2009-10-16 | 2012-05-23 | 出光兴产株式会社 | Fluorene-containing aromatic compound, material for organic electroluminescent element, and organic electroluminescent element using same |
TW201211047A (en) | 2010-06-10 | 2012-03-16 | Gilead Sciences Inc | Methods for treating HCV |
EP2797586A1 (en) * | 2011-12-29 | 2014-11-05 | AbbVie Inc. | Solid compositions comprising an hcv inhibitor |
US9056860B2 (en) | 2012-06-05 | 2015-06-16 | Gilead Pharmasset Llc | Synthesis of antiviral compound |
KR20140119012A (en) * | 2013-01-31 | 2014-10-08 | 길리어드 파마셋 엘엘씨 | Combination formulation of two antiviral compounds |
-
2013
- 2013-03-13 US US13/800,374 patent/US8969588B2/en active Active
- 2013-05-31 TW TW102119443A patent/TW201408661A/en unknown
- 2013-06-03 UY UY0001034844A patent/UY34844A/en not_active Application Discontinuation
- 2013-06-03 AR ARP130101956 patent/AR091259A1/en unknown
- 2013-06-04 WO PCT/US2013/044138 patent/WO2013184698A1/en active Application Filing
- 2013-06-04 MX MX2014014563A patent/MX2014014563A/en unknown
- 2013-06-04 IN IN2644MUN2014 patent/IN2014MN02644A/en unknown
- 2013-06-04 CN CN201380032193.2A patent/CN104379584A/en active Pending
- 2013-06-04 RU RU2014150437A patent/RU2014150437A/en not_active Application Discontinuation
- 2013-06-04 CA CA2875507A patent/CA2875507A1/en not_active Abandoned
- 2013-06-04 ES ES13729569.7T patent/ES2694759T3/en active Active
- 2013-06-04 KR KR20147037165A patent/KR20150028971A/en not_active Application Discontinuation
- 2013-06-04 SG SG11201408013WA patent/SG11201408013WA/en unknown
- 2013-06-04 PT PT13729569T patent/PT2855478T/en unknown
- 2013-06-04 EP EP13729569.7A patent/EP2855478B1/en active Active
- 2013-06-04 JP JP2015516143A patent/JP2015518891A/en active Pending
- 2013-06-04 BR BR112014030400A patent/BR112014030400A2/en not_active Application Discontinuation
- 2013-06-04 CN CN201510929740.8A patent/CN105524050A/en active Pending
- 2013-06-04 AU AU2013271768A patent/AU2013271768B2/en not_active Ceased
-
2014
- 2014-11-30 IL IL236004A patent/IL236004A0/en unknown
-
2015
- 2015-01-20 US US14/600,911 patent/US9139570B2/en active Active
- 2015-06-23 HK HK15105959.1A patent/HK1205127A1/en unknown
- 2015-08-13 US US14/825,386 patent/US9682987B2/en active Active
-
2017
- 2017-04-19 JP JP2017083097A patent/JP2017128605A/en active Pending
- 2017-05-26 US US15/607,326 patent/US20170327488A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2855478B1 (en) | 2018-08-08 |
ES2694759T3 (en) | 2018-12-27 |
TW201408661A (en) | 2014-03-01 |
IL236004A0 (en) | 2015-02-01 |
US20150141659A1 (en) | 2015-05-21 |
EP2855478A1 (en) | 2015-04-08 |
MX2014014563A (en) | 2015-07-06 |
US8969588B2 (en) | 2015-03-03 |
WO2013184698A1 (en) | 2013-12-12 |
US9139570B2 (en) | 2015-09-22 |
AU2013271768B2 (en) | 2018-05-17 |
CN105524050A (en) | 2016-04-27 |
KR20150028971A (en) | 2015-03-17 |
UY34844A (en) | 2013-12-31 |
US20150344488A1 (en) | 2015-12-03 |
JP2017128605A (en) | 2017-07-27 |
PT2855478T (en) | 2018-11-21 |
US9682987B2 (en) | 2017-06-20 |
HK1205127A1 (en) | 2015-12-11 |
CA2875507A1 (en) | 2013-12-12 |
JP2015518891A (en) | 2015-07-06 |
CN104379584A (en) | 2015-02-25 |
BR112014030400A2 (en) | 2016-06-07 |
RU2014150437A (en) | 2016-08-10 |
AR091259A1 (en) | 2015-01-21 |
US20130324496A1 (en) | 2013-12-05 |
SG11201408013WA (en) | 2015-01-29 |
AU2013271768A1 (en) | 2015-01-15 |
US20170327488A1 (en) | 2017-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN02644A (en) | ||
WO2014100779A8 (en) | Methods for production of platelets from pluripotent stem cells and compositions thereof | |
UA110354C2 (en) | Anti-viral compounds | |
WO2012082672A3 (en) | Process and intermediates for preparing macrolactams | |
IL229193A0 (en) | Pyridin-2(1h)-one derivatives useful useful as medicaments for the treatment of myeloproliferative disorders,transplant rejection,immune-mediated and inflammatory diseases | |
MY160596A (en) | Spiroindolinone pyrrolidines | |
IL214449A0 (en) | Systems and methods for maintaining the dominance and increasing the bimoss production of nannochloropsis in an algae cultivation system | |
WO2014096425A3 (en) | Prodrugs of monomethyl fumarate (mmf) | |
MX2015003124A (en) | Enzalutamide polymorphic forms and its preparation. | |
ZA201403678B (en) | Methods and systems for growing plants using silicate-based substrates,cultivation of enhanced photosynthetic productivity and photosafening by utilization of exogenous glycopyranosides for endogenous glycopyranosyl-protein derivatives ,and formulations,processes and systems for the same | |
MX2014001945A (en) | Process and intermediates for preparing macrolactams. | |
MY165238A (en) | Substituted pyrrolidine-2-carboxamides | |
MX336347B (en) | Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle. | |
MX339533B (en) | Dac hyp compositions and methods. | |
PL2729452T3 (en) | Process for preparing porous metal-organic framework composed of zinc methylimidazolate | |
MX2014002936A (en) | Novel betulinic acid derivatives with antiviral activity. | |
IL222248A0 (en) | Process for the preparation of pyrrolines from gamma-nitroketones and use of the gamma-nitroketones as pesticidal agents | |
PL2872465T3 (en) | Process for the preparation of carboxylic acid esters of a mixture of structually branched C9-monocarboxylic acids starting from 2-ethylhexanol, carboxylic acid esters of triethylene glycol, neopentyl glycol and 1,3-butanediol of this mixture as well as their use | |
EP2789601A4 (en) | Method for producing fatty acid monoglyceride containing mixture | |
WO2011050095A3 (en) | Prevention and treatment of post-operative cognitive dysfunction (pocd) | |
IN2014MN02467A (en) | ||
MX353863B (en) | Method for preparing a solid form of acetic acid and products thereof. | |
MX2014004083A (en) | Method of isolating ingenol. | |
ZA201408883B (en) | Method and system for improving the productivity of calling agents and call yield | |
IN2014DN00137A (en) |